Combined drug therapy may delay melanoma progression

Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.

Study finds mutation in melanoma sensitive to drug

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

New drug mutes more melanomas

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.

Investigators seek clues to resistance to melanoma drug

Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug.

Sosman named to ‘Dream Team’ of cancer investigators

Jeffrey Sosman named to melanoma research ‘Dream Team’